Developing novel lentiviral vectors into clinical products

Anna Leath, Kenneth Cornetta

12 Scopus citations

Abstract

Gene therapy vectors based on murine retroviruses have now been in clinical trials for over 20 years. During that time, a variety of novel vector pseudotypes were developed in an effort to improve gene transfer. Lentiviral vectors are now in clinical trials and a similar evolution of vector technology is anticipated. These modifications present challenges for those producing large-scale clinical materials. This chapter discusses approaches to process development for novel lentiviral vectors, highlight considerations, and methods to be incorporated into the development schema.

    Fingerprint

Keywords

  • Clinical vector production
  • Gene therapy vectors
  • Lentiviral vectors
  • Replication competent lentivirus
  • Vector certification
  • Vector pseudotypes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this